The impact of competing risks on the observed rate of chronic hepatitis C progression

被引:25
作者
Kim, WR
Poterucha, JJ
Benson, JT
Therneau, TM
机构
[1] Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Rochester, MN 55905 USA
关键词
D O I
10.1053/j.gastro.2004.06.052
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: In previous studies about the natural history of chronic hepatitis C (CHC), age at the time of infection correlated with the rate at which hepatic fibrosis progresses. The presence of a competing risk, namely higher mortality from natural causes, may contribute to this observation. A simulation experiment was conducted to measure the magnitude of the effect of competing risks on the observed rate of fibrosis progression of CHC. Methods: A computer-based probabilistic model was created in which fibrosis of CHC progressed from stage 0 to 4 (cirrhosis) in 20-year-old and 50-year-old male and female cohorts. The rate of fibrosis progression was randomly assigned to each simulated individual from a distribution common to all age- and sex-specific cohorts. The cohorts also experienced mortality from natural causes according to the 2000 census data. Results: The observed median time to reach cirrhosis for the 50-year-old cohorts was 20.4 +/- 0.2 years compared with 29.7 +/- 0.2 for the 20-year-old cohorts (P < 0.01). The median time to reach cirrhosis in men was 24.2 +/- 0.6 years compared with 25.9 +/- 0.6 in women (P = 0.01). Overall, the observed rate of progression was slowest among young women. Similarly, accelerating mortality from natural causes, simulating the impact of comorbid conditions that shorten survival, reduced the observed time to reach cirrhosis. Conclusions: Even if the underlying rate of fibrosis progression in CHC was held constant, the time to reach cirrhosis will be observed to be substantially shorter in subjects with a higher competing mortality.
引用
收藏
页码:749 / 755
页数:7
相关论文
共 30 条
[1]   Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: Impact of protease inhibitor therapy [J].
Benhamou, Y ;
Di Martino, V ;
Bochet, M ;
Colombet, G ;
Thibault, V ;
Liou, A ;
Katlama, C ;
Poynard, T .
HEPATOLOGY, 2001, 34 (02) :283-287
[2]   Chronic hepatitis C: Effect of alcohol on hepatitic activity and viral titre [J].
Cromie, SL ;
Jenkins, PJ ;
Bowden, DS ;
Dudley, FJ .
JOURNAL OF HEPATOLOGY, 1996, 25 (06) :821-826
[3]   Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death [J].
Degos, F ;
Christidis, C ;
Ganne-Carrie, N ;
Farmachidi, JP ;
Degott, C ;
Guettier, C ;
Trinchet, JC ;
Beaugrand, M ;
Chevret, S .
GUT, 2000, 47 (01) :131-136
[4]   Estimating progression to cirrhosis in chronic hepatitis C virus infection [J].
Freeman, AJ ;
Dore, GJ ;
Law, MG ;
Thorpe, M ;
Von Overbeck, J ;
Lloyd, AR ;
Marinos, G ;
Kaldor, JM .
HEPATOLOGY, 2001, 34 (04) :809-816
[5]  
Geissler M, 1997, J IMMUNOL, V159, P5107
[6]  
Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO
[7]  
2-O
[8]   Course and outcome of hepatitis C [J].
Hoofnagle, JH .
HEPATOLOGY, 2002, 36 (05) :S21-S29
[9]   Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin [J].
Kenny-Walsh, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (16) :1228-1233
[10]   Long-term follow-up of IgM monoclonal gammopathy of undetermined significance [J].
Kyle, RA ;
Therneau, TM ;
Rajkumar, SV ;
Remstein, ED ;
Offord, JR ;
Larson, DR ;
Plevak, MF ;
Melton, LJ .
BLOOD, 2003, 102 (10) :3759-3764